氯沙坦对充血性心力衰竭患者肿瘤坏死因子和内皮素的影响

Effect of Losartan on TNF and ET in patient with congestive heart failure

目的 评价氯沙坦对充血性心力衰竭患者 (CHF)肿瘤坏死因子和内皮素的影响。方法 随即选取 80名CHF患者 ,随机分为氯沙坦组和培哚普利 2组 ,分别于治疗前 ,治疗后 1周、8周测定所有患者ET - 1、TNF -α、AngⅡ水平。另选 4 0例健康人为对照组。结果 CHF患者血浆ET - 1、TNF -α、AngⅡ均显著高于正常对照组 ,氯沙坦组、培哚普利组患者心功能改善率、恶化率及病死率均无显著差异。氯沙坦治疗后血浆AngⅡ水平比培哚普利明显提高。结论 氯沙坦可获得有益的临床效应和神经激素效应 ,并有较好的耐受性。

Objective It is to evaluate the effect of Losartan on TNF and ET in patients with congestive heart failure (CHF). Methods 80 patients with CHF were randomly divided into Losartan group and Perindopril group. The plasma ET-1, TNF-α and AngⅡ of all the patients were measured before treatment and the first and eighth week after treatment. 40 healthy volunteers were chosen as control group. Results The levels of plasma ET-1, TNF-α and AngⅡ in patients with CHF were all obviously higher than that in control group. There were no differences in improvement rate and aggravation rate of heart function and case-fatality rate between Losartan group and Perindopril group. The plasma AngⅡ level was higher in Losartan group than that in Perindopril group. Conclusion Losartan has salutary clinical and neurohormone effect and better tolerance.